OKYO Pharma Ltd (LSE: OKYO, NASDAQ: OKYO), a biopharmaceutical company focused on ophthalmology, is set to present two papers on their treatment for dry eye disease (DED), OK-101, at the
OKYO Pharma Ltd (LSE: OKYO, NASDAQ: OKYO), a biopharmaceutical company focused on ophthalmology, is set to present two papers on their treatment for dry eye disease (DED), OK-101, at the
Activation of First Clinical Trial Site in the U.S
The AIM-All Share Index, which rose by 0.6% to 804 points, made only slight gains across the wider market. However, the FTSE 100’s blue-chip companies surged 3% to 7,628 points
This post was written by Zak Mir, a Technical Analyst, Events Host, Presenter, CEO Interviewer and established Market Commentator.
This post was written by Zak Mir, a Technical Analyst, Events Host, Presenter, CEO Interviewer and established Market Commentator.
In an effort to prevent the spread of instability following the industry’s most tumultuous week since the 2008 financial crisis, the Bank of England has instructed British lenders to disclose
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s charts are FTSE 100, Dax, Dow, Bitcoin, Argo Blockchain, Asiamet,
OKYO Pharma Ltd (LSE: OKYO, NASDAQ: OKYO) announced that the ClinicalTrials.gov public website (ClinicalTrials.gov Identifier: NCT05759208) now includes information about its trial that assesses the safety and effectiveness of OK-101
This post was written by Zak Mir, a Technical Analyst, Events Host, Presenter, CEO Interviewer and established Market Commentator.
This post was written by Zak Mir, a Technical Analyst, Events Host, Presenter, CEO Interviewer and established Market Commentator.
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s charts are FTSE 100, Dax, Dow, Bitcoin, Amur, BSF, Celadon,